DPCP for the Treatment of Alopecia Areata

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
Alopecia Areata
Interventions
DRUG

Diphenylcyclopropenone (DPCP) Ointment

All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks

Trial Locations (1)

55455

University of Minnesota Department of Dermatology, Minneapolis

All Listed Sponsors
collaborator

National Alopecia Areata Foundation

OTHER

lead

University of Minnesota

OTHER

NCT03651752 - DPCP for the Treatment of Alopecia Areata | Biotech Hunter | Biotech Hunter